Trial Profile

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACLX-001 (Primary) ; Anitocabtagene autoleucel Arcellx (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man; Proof of concept
Sponsors Arcellx; Kite Pharma

Most Recent Events

11 Feb 2025 According to a Gilead Sciences media release, data from this trial were presented at the American Society of Hematology 2024 Annual Meeting.
05 Nov 2024 According to a Gilead Sciences media release, data from this trial will be presented in oral presentations, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Dec 7-10).
17 Jul 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com